The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

Abstract Background Systemic treatment of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the introduction of targeted therapies. The analysis of circulating tumor DNA (ctDNA) is a valuable approach to monitor the clonal evolution of tumors during treatment with EGFR-tyros...

Full description

Bibliographic Details
Main Authors: Marzia Del Re, Eleonora Rofi, Carla Cappelli, Gianfranco Puppo, Stefania Crucitta, Simona Valeggi, Antonio Chella, Romano Danesi, Iacopo Petrini
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Circulating tumor DNA
NSCLC
EGFR mutations
Treatment monitoring
EGFR-TKIs
Digital droplet PCR
Online Access:http://link.springer.com/article/10.1186/s12885-019-5604-6

Internet

http://link.springer.com/article/10.1186/s12885-019-5604-6

Similar Items